Introduction Mayo Clinic dosed the first patient last week with Ac-225-DOTATATE radiotherapeutic (RYZ101), an alpha-emitter, by RayzeBio (a BMS company), for metastatic, estrogen receptor–positive (ER⁺), human epidermal growth factor receptor
Introduction Ac-225 is an α-emitting radionuclide with a half-life of 9.9 days. Its high energy, multi-day half-life and short travel distance in tissues makes it an attractive radioisotope for targeted
Useful for enthusiasts, investors, commercial, management, production and supply chain professionals. Actinium‑225 (Ac‑225) is a highly sought-after radionuclide for targeted alpha therapy (TAT), an emerging cancer treatment modality. This report
Prostate cancer is one of the most prevalent cancers among men worldwide. Targeted PET imaging in prostate cancer plays a vital role in detecting metastasis to guide treatment decisions. In
Actinium-225 (Ac-225), 136Ac89, is an important radioisotope in nuclear medicine with applications in the targeted alpha therapy (TAT) in oncology. Ac-225 contains 89 protons and 136 Neutrons, corresponding to atomic mass
Alzheimer’s disease is a complex brain disorder that affects memory, thinking, and behavior, leading to disability and loss of independence. Currently, nearly 10% of Americans 65 or older, an estimated
This blog discusses radiohybrids, theranostics and theranostic pairs. Radiohybrids is a modality in nuclear medicine that allows diagnostic imaging or therapeutic treatment with the same molecular entity depending on the radioelement in the molecule.
The “FIND” Act, or Facilitating Innovative Nuclear Diagnostics Act, aims to improve access to advanced radiodiagnostic imaging for early diagnosis of heart disease, neurological disorders, and cancer to enhance patient
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
Radiotracers are essential tools in nuclear medicine, used for diagnosing and monitoring a variety of diseases, including cancer, brain and heart conditions. However, their production is highly specialized, time-sensitive, and
Introduction Mayo Clinic dosed the first patient last week with Ac-225-DOTATATE radiotherapeutic (RYZ101), an alpha-emitter, by RayzeBio (a BMS company), for metastatic, estrogen receptor–positive (ER⁺), human epidermal growth factor receptor
Introduction Ac-225 is an α-emitting radionuclide with a half-life of 9.9 days. Its high energy, multi-day half-life and short travel distance in tissues makes it an attractive radioisotope for targeted
Useful for enthusiasts, investors, commercial, management, production and supply chain professionals. Actinium‑225 (Ac‑225) is a highly sought-after radionuclide for targeted alpha therapy (TAT), an emerging cancer treatment modality. This report
Prostate cancer is one of the most prevalent cancers among men worldwide. Targeted PET imaging in prostate cancer plays a vital role in detecting metastasis to guide treatment decisions. In
Actinium-225 (Ac-225), 136Ac89, is an important radioisotope in nuclear medicine with applications in the targeted alpha therapy (TAT) in oncology. Ac-225 contains 89 protons and 136 Neutrons, corresponding to atomic mass
Alzheimer’s disease is a complex brain disorder that affects memory, thinking, and behavior, leading to disability and loss of independence. Currently, nearly 10% of Americans 65 or older, an estimated
This blog discusses radiohybrids, theranostics and theranostic pairs. Radiohybrids is a modality in nuclear medicine that allows diagnostic imaging or therapeutic treatment with the same molecular entity depending on the radioelement in the molecule.
The “FIND” Act, or Facilitating Innovative Nuclear Diagnostics Act, aims to improve access to advanced radiodiagnostic imaging for early diagnosis of heart disease, neurological disorders, and cancer to enhance patient
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
Radiotracers are essential tools in nuclear medicine, used for diagnosing and monitoring a variety of diseases, including cancer, brain and heart conditions. However, their production is highly specialized, time-sensitive, and
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the eReport.
